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Abstract
Background: Endometrial thickness is regarded as an indicator of the receptivity of the
endometrium. Patients preparing for frozen embryo transfer need some interventions
in case their endometrium is thin.
Objective: This study aimed to compare the clinical outcomes of oral administration
of estradiol valerate with its vaginal type in women with inappropriate endometrial
thickness.
Materials and Methods: This cross sectional study comprised of 79 women (cycles)
who had undergone frozen-thawed embryo transfer. On the 13th day of the cycle,
vaginal sonography was performed in case the thickness of the endometrium was
< 7 mm; in the oral group, the patients continued using oral estradiol valerate
tablet. However, in the vaginal group, the participants applied estradiol valerate tablet
vaginally. Finally, the chemical and clinical pregnancy rate, also, early miscarriage rate
were compared between the two groups.
Results: The early miscarriage rate was lower in the vaginal group in comparison
with the oral group (p = 0.040). Women in the vaginal group showed a lower rate of
chemical pregnancy compared to the oral group, but this difference was not statistically
significant (25.0 vs. 34.4%, p = 0.440). The rate of clinical pregnancy in the two groups
was not statistically significant, although the vaginal group had a higher pregnancy rate
(22.5% vs. 15.6%, p = 0.464), especially in women older than 34 years (37.5% vs. 11.1%,
p = 0.355).
Conclusion: Vaginal administration of estradiol tablet in women with thin endometrium
leads to a lower rate of early miscarriage.
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1. Introduction
Due to the advancement of laboratory
equipment and protocols of ovarian stimulation,
infertile patients who receive in vitro
fertilization/intracytoplasmic sperm injection
(IVF/ICSI) treatment can bear the potential for extra
healthy embryos frozen for future transfer. As a
major part of IVF/ICSI techniques, frozen-thawed
embryo transfer (FET) enjoys some advantages
including i) the prevention of IVF/ICSI complications
such as ovarian hyperstimulation syndrome,
ii) a rise in the rate of cumulative pregnancy,
and iii) better endometrium synchronism (1).
Endometrial thickness is regarded as an indicator
of the receptivity of the endometrium and
as a prognostic factor in the transfer of an
embryo in the course of IVF/ICSI treatment.
Appropriate endometrial thickness is crucial in
the success of pregnancy, and many studies
report low rates of pregnancy due to thin
endometrium.
Clinicians have varying perspectives on
the ideal thickness of the endometrium for
conception (2). It has been verified that the rate
of pregnancy and implantation is negatively
correlated with endometrial thickness < 7
mm and responsible for a higher probability
of miscarriage (3). Many protocols exist for
the preparation of the endometrium in FET
cycles, the most popular one of which is
hormonal replacement treatment utilizing
exogenous estradiol and progesterone
(1). Patients preparing for FET need the
supplementation of extra estrogen or some
other interventions in case their endometrium is
thin (4).
This study was designed to investigate
the clinical outcomes of endometrial
preparation by oral compared with vaginal
administration of estradiol valerate in
women with inadequate endometrial
thickness after 12 days of taking estrogen
supplementation.
2. Materials and Methods
In this cross-sectional study, the medical records
of 79 women underwent endometrial preparation
for FET treatment in the Research and Clinical
Center for Infertility, Yazd, Iran between June
2018 and January 2019 were reviewed. Our
inclusion criteria were endometrial thickness <
7 mm measured by vaginal ultrasonography on
day 13 cycle, after administration of 6 mg oral
estradiol valerate/day from the second day of the
menstrual cycle. The exclusion criteria comprised
of donor oocyte recipients and gestational
carriers.
The preparation of the endometrium
in all participants started with the oral
administration of the estradiol valerate tablet
6 mg/day (Aburaihan Co., Tehran, Iran) from
the second day of the menstrual cycle.
On the 13th day, vaginal ultrasonography
was employed in order to measure the
thickness of the endometrium. In case the
thickness of the endometrium was < 7 mm,
the women would be administered with
10 mg/day estradiol valerate. The oral or
vaginal administration of the estradiol valerate
depended on the clinician’s decision; 36
women (cycles) have been treated with the
oral estradiol valerate (OE group) and 43
women (cycles) with estradiol valerate tablet
vaginally (VE group). When the endometrial
thickness reached ≥ 8mm, all women were
administered with 400 mg of Cyclogest®
vaginal pessaries (Cox Pharmaceuticals,
Barnstaple, UK) twice a day. The embryo
transfer was conducted three days after
the administration of progesterone for
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cleavage embryos and five days after for
blastocyst. After embryo transfer, all the
patients received estradiol valerate orally
and progesterone suppository. In the cases
pregnancy occurred, administration continued
until 10th week of the gestational age. Twelve
days following the embryo transfer, chemical
pregnancy was determined using serum
βhCG > 50 IU/L. Moreover, 14 days following
a positive βhCG, clinical pregnancy was
verified by identifying fetal heartbeats in
sonography. Early miscarriage was defined
as the loss of pregnancy before 12th week of
gestation.
2.1. Ethical consideration
All women signed the informed consent to
participate in this study. The study protocol
was approved by the Ethics Committee of Yazd
Reproductive Sciences Institute, Yazd, Iran (Code:
IR.SSU.RSI.REC.1397.026).
2.2. Statistical analysis
SPSS software (Statistical Package for the
Social Sciences, SPSS Inc., Chicago, Illinois,
USA) version 20.0, Students t test, and Chi-
square test were used for the statistical
calculations. A p-value < 0.05 was considered
as significant.
3. Results
There were no significant differences between
the two groups in the mean of age, body
mass index, duration of infertility, and type
of infertility (Table I). Total cancelation due
to inappropriate endometrium thickness was
three cycles in the VE group, while it was four
cycles in the OE group (7.0% vs 11.1%; p = 0.696).
The duration of estradiol supplementation (p
= 0.73) and total dose of estradiol (p = 0.847)
were similar in both groups. There was no
significant difference between the two groups
in the terms of endometrial thickness on day 13
and endometrial thickness on the day of transfer
(Table II).
Althoughwomen in the VE group obtained lower
chemical pregnancy rate compared with the OE
group (p = 0.440), yet clinical pregnancy rate was
higher for them (p = 0.464), especially for the
women who were older than 34 yr (p = 0.355). The
early miscarriage rate was lower in the VE group
in comparison with the OE group (p = 0.040) (Table
III).
Table I. Basic characteristics of the participants in the two groups
Variables VE group (n = 43) OE group (n = 36) P-value
Age (yr) * 33.09 ± 5.56 32.00 ± 5.45 0.38
age > 34 yr** 18 (41.9) 12 (33.3) 0.49
BMI* 26.72 ± 5.10 24.92 ± 4.46 0.30
Duration of infertility (yr)** 8.4651 ± 5.27618 6.55 ± 4.23 0.08
Type of infertility**
Primary 30 (69.8) 26 (74.3)
Secondary 13 (30.2) 9 (25.7)
0.65
*Data presented as Mean ± SD. (Student t test); **Data presented as n (%) (Chi-square test)
VE, Vaginal estradiol; OE, Oral estradiol; BMI, Body mass index
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Table II. Frozen embryo transfer cycle characteristics in the two groups
Variables VE group (n = 43) OE group (n = 36) P-value
Duration of estradiol supplementation (day) * 16.58 ±2.10 16.75 ± 2.24 0.73
Total dose of estrogen (mg) * 122.18 ± 22.81 123.16 ± 21.78 0.84
Quality of transferred embryos**
A 8 (20.0) 4 (12.5)
B 23 (57.5) 16 (50.0)
C 3 (7.5) 6 (18.8)
Blast 6 (15.0) 6 (18.8)
0.43
Number of transferred embryos* 1.81 ± 0.58 1.72 ± 0.65 0.51
ET on day 13 (mm) * 6.100.74 6.07± 0.65 0.87
ET on day of transfer (mm) * 8.18± 1.16 8.11 ± 1.35 0.80
ET increase after day 13 (mm) * 2.08± 1.28 2.03± 1.49 0.85
Total cycle cancelation** 3 (7.0) 4 (11.1) 0.69
*Data presented as Mean ± SD (Student t test); **Data presented as n (%) (Chi-square test)
VE, Vaginal estradiol; OE, Oral estradiol; ET, Endometrial thickness
Table III. Assisted reproductive techniques outcomes in frozen embryo cycles
Variable VE group (n = 40) OE group (n = 32) P-value
Chemical pregnancy rate/transfer* 10 (25.0) 11 (34.4) 0.440
Clinical pregnancy rate/transfer* 9 (22.5) 5 (15.6) 0.464
Clinical pregnancy rate in age > 34* 6 (37.5) 1 (11.1) 0.355
Early miscarriage rate* 1 (2.5) 6 (18.8) 0.040
*Data presented as n (%); Chi-square test
VE, Vaginal estradiol; OE, Oral estradiol
4. Discussion
This study identified that vaginal administration
of estradiol in women with thin endometrium leads
to a lower rate of early miscarriage. In order to
induce endometrial receptivity in the cycles of the
cryopreserved embryo transfer, progesterone and
estrogen are required. Scores of methods and
routes of administration of exogenous estradiol
are available to reproductive health providers (5).
Evidenced by the current published literature,
recommending an ideal method for endometrial
preparation in the FET is still amatter of controversy
(6).
For the assessment of endometrial proliferation,
the measurement of the endometrial thickness
using ultrasound is regarded as a reproducible
and simple method. The lowest rates of pregnancy
were relevant to the endometrial thickness of
> 14 mm and < 7 mm (7). The incidence of
thin endometrium in ART has been stated to
be 1.5 to 9.1% (8). As a first-line agent, oral
administration of estradiol between day 10th and
14th may be the simplest route, at either an
increasing or a constant dose. If insufficient
endometrialb thickness is observed, this course
can be extended by changing the route of
administration to percutaneous or vaginal (5).
In order to improve ET in patients with
unresponsive endometrium, several methods have
been used till date, including pentoxifylline-vitamin
E, aspirin, G-CSF, autologous platelet-rich-plasma,
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sildenafil, and human chorionic gonadotropin (3,
9-12). However, none of these methods has been
reported to be superior to the others.
Parenteral routes of administration, including
intramuscular, vaginal, and transdermal circumvent
the liver first-pass metabolism of E2 (8, 13). The
excessive exposure of the liver due to liver first-
pass effect inherent to oral administration can
lead to a higher risk of veno-thromboembolism
accidents, especially in susceptible women.
Vaginal E2, especially in patients with poor
endometrial response to E2, can be a valuable
alternative. Although creams with special designs
are available, oral tablets are administered
vaginally by many professionals (14). In the present
study, we also administered oral estradiol tablets
vaginally to the VE group. In a study conducted by
Zolghadri and colleagues, Vagifem was compared
with vaginal Premarin (15). However, oral estradiol
tablets are more cost-effective and convenient. E2,
administered vaginally, can be absorbed into the
circulation adequately and by the endometrium
selectively. High levels of serum-approximately
eight times higher than the oral administration-are
obtained; this seems to be remarkably a highly
efficient method for the delivery of E2 directly to
the intended tissue with even higher endometrial
tissue levels observed (80 times higher) (5).
Despite the higher levels of serum E2, it can
be as safe as the equal oral dose. There is no
difference in the levels of sex hormone-binding
globulin or in the patients’ cholesterol profile (16).
Following embryo transfer in both groups of the
study, estradiol tablets were administered orally.
Estrogen concentrations were reported to be
positively correlated with the frequency of uterine
contraction (17).
In this study, VE and OE groups demonstrated
comparable rates of clinical and chemical
pregnancies. Correspondingly in another study,
Liao and colleagues identified pregnancy
outcomes being comparable in females bearing
thin endometria administered with estradiol orally
or vaginally (4). Fanchin and colleagues compared
vaginal and oral routes in 39 infertile females by
observing uterine perfusion and ET on day 14th
following the E2 administration. They concluded
that the vaginal route can trigger better ET and
uterine perfusion than the oral route (18).
Contrary to the above, Doyle and colleagues
reported that adding vaginal E2 can induce a
rapid increase in the levels of serum E2 and thus
contribute to a lower rate of live birth as well
as a higher rate of miscarriage. The reason, as
they concluded, is that an increase in the level
of serum E2 over the threshold of 200 pg/ml of
the natural menstrual cycle can produce negative
effects arising from supraphysiologic E2 levels (19).
In contrast, the present study demonstrated a lower
rate of early miscarriage in the VE group (p < 0.05).
For implantation to occur successfully, the
endometrium needs to undergo key alterations
to receive the growing embryo within a defined
period known as the ”implantation window”. This
complicated process is adjusted by the interaction
of adhesion molecules, ovarian hormones, growth
factors, and cytokines (7). Accordingly, one may
deduce that vaginal estradiol can improve the
endometrial development by affecting not only
the thickness of the endometrium but also the
microenvironment of the endometrium (4).
5. Conclusion
The findings of this study revealed that women
with age>34yr had more pregnancy rates in
the VE group, although the differences were
not statistically significant. Due to no significant
differences in pregnancy rates between two study
groups the lower risk of thromboembolism in the
vaginal route because lack of hepatic metabolism
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compared to the oral route, so this method is
recommended especially in women at higher risk
of thromboembolism. Also, vaginal administration
of estradiol tablet in women with thin endometrium
leads to a lower rate of early miscarriage.
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